Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Untitled source document

No live link available for this source.

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The work coming out of the KU Leuven Sports Analytics Lab is genuinely useful and clubs apply it for a range of purposes

    60% confidence
  • Manual soccer game annotation is a nightmare for data analysts, taking up to six hours per game

    60% confidence
  • Jesse Davis's lab is the most influential sports analytics lab in soccer

    60% confidence
  • Over the last five to ten years, the number of long shots in soccer has dramatically increased as a result of data showing their value

    60% confidence
  • When the ball is in the middle third of the pitch, kicking it out of bounds on the opponent's side can put the kicking team within 10 actions of a goal

    60% confidence
  • Chelsea could gain 1.6 more goals per season by shooting from distance 20% more often

    60% confidence
  • Jan Van Haaren and the KU Leuven lab laid the intellectual foundations of how soccer is analyzed today

    60% confidence
  • Davis is motivated to solve problems that arise in real settings and see his work have an impact

    60% confidence
  • Club Brugge's collaboration with the KU Leuven lab is centered on translating the team's football philosophy into measurable, data-driven outputs

    60% confidence
  • The vast majority of soccer actions don't lead to a goal or even a shot, making it hard to derive a winning strategy from data

    60% confidence
  • Many people in industry use the KU Leuven Sports Analytics Lab's open-source code in their daily workflows

    60% confidence
  • Significant progress has been made on transformer-based automated soccer annotation, but the problem remains quite hard

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com